CD44 Family Proteins in Gastric Cancer: a Meta-analysis and Narrative Review

Overview

Journal Int J Clin Exp Med

Specialty General Medicine

Date 2015 Jun 12

PMID 26064255

Citations 10

Authors

Ying Wu

Zhi Li

Chenlu Zhang

Kai Yu

Zan Teng

Guoliang Zheng

Shuang Wang

Yunpeng Liu

Lei Cui

Xiaosong Yu

Affiliations

Soon will be listed here.

Abstract

With a meta-analysis and narrative review, we evaluated the clinical and prognostic role of all CD44 family proteins in gastric cancer (GC). Literatures published up to August 2014 were searched on PubMed. Among the 37 eligible studies (6606 patients), 34 were included in meta-analysis, and 10 were subjected to narrative review. With meta-analysis, standard CD44 (CD44s) was demonstrated to predict reduced overall survival (OS) (HR = 1.93, 95% CI: 1.58-2.34, PHR = 0.0222) and disease free survival (HR = 3.13, 95% CI: 1.02-9.68, PHR = 0.0469), advanced N-stage (RR = 1.12, 95% CI: 1.04-1.21, PRR = 0.0019), and distant metastasis (RR = 2.14, 95% CI: 1.46-3.14, PRR < 0.0001) of GC. CD44 variant 6 (CD44v6) in GC might influence OS (5 studies; HR = 1.27, 95% CI: 0.75-2.14, PHR = 0.3783; 4 studies; HR = 1.52, 95% CI: 1.09-2.14, PHR = 0.0139), while significantly associated with N-stage (RR = 1.23, 95% CI: 1.03-1.48, PRR = 0.0240), M-stage (RR = 2.54, 95% CI: 1.08-6.00, PRR = 0.0333), TNM-stage (RR = 1.72, 95% CI: 1.18-2.50, PRR = 0.0045), Lauren type (RR = 0.67, 95% CI: 0.50-0.91, PRR = 0.0106), lymphatic invasion (RR = 1.13, 95% CI: 1.04-1.23, PRR = 0.0057), and liver metastasis (RR = 3.20, 95% CI: 1.94-5.27, PRR < 0.0001) of the disease. Moreover, a narrative review was performed for CD44 isoforms, such as v3, v5, v7, v8-10, and v9, in GC. In conclusion, CD44s and CD44v6 as evaluated by immunohistochemistry, respectively, predicts the prognosis and disease severity of GC.

Citing Articles

Identification of the key genes controlling stomach adenocarcinoma stem cell characteristics via an analysis of stemness indices.

Wang G, Wu Z, Huang Y, Li Y, Bai Y, Luo Z J Gastrointest Oncol. 2022; 13(2):593-604.

PMID: 35557559 PMC: 9086058. DOI: 10.21037/jgo-22-244.

Treatment Strategies of Gastric Cancer-Molecular Targets for Anti-angiogenic Therapy: a State-of-the-art Review.

Tyczynska M, Kedzierawski P, Karakula K, Januszewski J, Kozak K, Sitarz M J Gastrointest Cancer. 2021; 52(2):476-488.

PMID: 33761051 PMC: 8131337. DOI: 10.1007/s12029-021-00629-7.

Prognostic Biomarkers for Gastric Cancer: An Umbrella Review of the Evidence.

Zhou C, Zhong X, Song Y, Shi J, Wu Z, Guo Z Front Oncol. 2019; 9:1321.

PMID: 31850212 PMC: 6895018. DOI: 10.3389/fonc.2019.01321.

A CD44-specific peptide, RP-1, exhibits capacities of assisting diagnosis and predicting prognosis of gastric cancer.

Li W, Jia H, Wang J, Guan H, Li Y, Zhang D Oncotarget. 2017; 8(18):30063-30076.

PMID: 28415792 PMC: 5444726. DOI: 10.18632/oncotarget.16275.

Prognostic impact of CD44-positive cancer stem-like cells at the invasive front of gastric cancer.

Kodama H, Murata S, Ishida M, Yamamoto H, Yamaguchi T, Kaida S Br J Cancer. 2016; 116(2):186-194.

PMID: 27931044 PMC: 5243989. DOI: 10.1038/bjc.2016.401.

References

Mirecka J, Marx D, Schauer A . Immunohistochemical localization of CD44 variants 5 and 6 in human gastric mucosa and gastric cancer. Anticancer Res. 1995; 15(4):1459-65. View

Muller W, Schneiders A, Heider K, Meier S, Hommel G, Gabbert H . Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer. J Pathol. 1997; 183(2):222-7. DOI: 10.1002/(SICI)1096-9896(199710)183:2<222::AID-PATH923>3.0.CO;2-C. View

Hirata K, Suzuki H, Imaeda H, Matsuzaki J, Tsugawa H, Nagano O . CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence. Br J Cancer. 2013; 109(2):379-86. PMC: 3721391. DOI: 10.1038/bjc.2013.314. View

Yoshida G, Saya H . Inversed relationship between CD44 variant and c-Myc due to oxidative stress-induced canonical Wnt activation. Biochem Biophys Res Commun. 2013; 443(2):622-7. DOI: 10.1016/j.bbrc.2013.12.016. View

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

Jang B, Li Y, Graham D, Cen P . The Role of CD44 in the Pathogenesis, Diagnosis, and Therapy of Gastric Cancer. Gut Liver. 2011; 5(4):397-405. PMC: 3240781. DOI: 10.5009/gnl.2011.5.4.397. View

Li H, Guo L, Li J, Liu N, Qi R, Liu J . Expression of hyaluronan receptors CD44 and RHAMM in stomach cancers: relevance with tumor progression. Int J Oncol. 2000; 17(5):927-32. View

Klonisch T, Wiechec E, Hombach-Klonisch S, Ande S, Wesselborg S, Schulze-Osthoff K . Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol Med. 2008; 14(10):450-60. DOI: 10.1016/j.molmed.2008.08.003. View

Yamaguchi A, Saito M, Gio T, Iida A, Takeuchi K, Hirose K . Expression of CD44 variant exons 8-10 in gastric cancer. Jpn J Cancer Res. 1995; 86(12):1166-71. PMC: 5920665. DOI: 10.1111/j.1349-7006.1995.tb03310.x. View

10.

Saito H, Tsujitani S, Katano K, Ikeguchi M, Maeta M, Kaibara N . Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma. Cancer. 1998; 83(6):1094-101. View

11.

Ishigami S, Ueno S, Arigami T, Uchikado Y, Setoyama T, Arima H . Prognostic impact of CD133 expression in gastric carcinoma. Anticancer Res. 2010; 30(6):2453-7. View

12.

Songun I, Litvinov S, van de Velde C, Pals S, Hermans J, van Krieken J . Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer. 2005; 92(9):1767-72. PMC: 2362035. DOI: 10.1038/sj.bjc.6602519. View

13.

Parmar M, Torri V, Stewart L . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1999; 17(24):2815-34. DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. View

14.

Shi J, Yao D, Liu W, Wang N, Lv H, He N . Frequent gene amplification predicts poor prognosis in gastric cancer. Int J Mol Sci. 2012; 13(4):4714-4726. PMC: 3344242. DOI: 10.3390/ijms13044714. View

15.

Hong R, Lee W, Shun C, Chu J, Chen Y . Expression of CD44 and its clinical implication in diffuse-type and intestinal-type gastric adenocarcinomas. Oncology. 1995; 52(4):334-9. DOI: 10.1159/000227485. View

16.

Li K, Dan Z, Nie Y . Gastric cancer stem cells in gastric carcinogenesis, progression, prevention and treatment. World J Gastroenterol. 2014; 20(18):5420-6. PMC: 4017057. DOI: 10.3748/wjg.v20.i18.5420. View

17.

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

18.

Setala L, Lipponen P, Tammi R, Tammi M, Eskelinen M, Alhava E . Expression of CD44 and its variant isoform v3 has no prognostic value in gastric cancer. Histopathology. 2001; 38(1):13-20. DOI: 10.1046/j.1365-2559.2001.01038.x. View

19.

Chen J, Li T, Liu Q, Jiao H, Yang W, Liu X . Clinical and prognostic significance of HIF-1α, PTEN, CD44v6, and survivin for gastric cancer: a meta-analysis. PLoS One. 2014; 9(3):e91842. PMC: 3960154. DOI: 10.1371/journal.pone.0091842. View

20.

Nagano O, Saya H . Mechanism and biological significance of CD44 cleavage. Cancer Sci. 2004; 95(12):930-5. PMC: 11159127. DOI: 10.1111/j.1349-7006.2004.tb03179.x. View